Semaglutide in Australia

Legal status, what it is, and the listed suppliers in Australia that list it.

Legal status in Australia

Prescription only. Listed in Schedule 4 of the Poisons Standard (June 2026).

As understood at 2026-09-26. Verify with the TGA.

What Semaglutide is

Semaglutide is a synthetic analogue of GLP-1, a hormone released by the gut after eating. Unlike most peptides on this site, it is an approved prescription medicine in all three launch countries, and its trial programme is among the largest in modern medicine.

Full Semaglutide page: targets and research →

Listed suppliers in Australia

1 of the 10 suppliers we list in Australia list Semaglutide. Listed, not endorsed: each row is the supplier’s own stated terms.

Au Peptide Labs Australia For laboratory research use only. Not for human consumption.

Clinical Research

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). New England Journal of Medicine. human 17,604 patients aged 45 or over with existing cardiovascular disease and a BMI of 27 or more, without diabetes; multicentre, double-blind, placebo-controlled

Once-weekly semaglutide in adults with overweight or obesity

Wilding JPH, Batterham RL, Calanna S, et al. (STEP 1 Study Group) (2021). New England Journal of Medicine. human adults with overweight or obesity, phase III, n=1961

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity

Garvey WT, Blüher M, Osorto Contreras CK, et al. (REDEFINE 1 Study Group) (2025). New England Journal of Medicine. human adults with overweight or obesity, without diabetes, phase 3a, n=3417

Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

Davies MJ, Bajaj HS, Broholm C, et al. (REDEFINE 2 Study Group) (2025). New England Journal of Medicine. human adults with overweight or obesity and type 2 diabetes, phase 3a, n=1206

Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial

Colhoun HM, Lincoff AM, Ryan D, et al. (2026). European Heart Journal. human humans, n=17,604, secondary (mediation) analysis of the SELECT randomised trial

SGLT2 inhibitors, semaglutide, and finerenone in diabetic kidney disease: a Bayesian network meta-analysis

He Z, Wang X, Zhang L, et al. (2026). Frontiers in Pharmacology. meta-analysis n=20,521 across six phase 3 randomised-trial datasets (CREDENCE, DAPA-CKD and EMPA-KIDNEY type 2 diabetes subgroups, FIDELIO-DKD, FIGARO-DKD, FLOW)

Comparative Effectiveness of Once-Weekly Semaglutide Versus Sulfonylureas, DPP4 Inhibitors, and Thiazolidinediones in Patients with Type 2 Diabetes and Chronic Kidney Disease

Amamoo J, Wang Y, Liu H, et al. (2026). Advances in Therapy. human adults with type 2 diabetes and chronic kidney disease, retrospective cohort from US insurance claims (2016 to 2023); sample 1 16,646 vs 33,197 (from the full text, per Social's check), sample 2 n not found

Oral Semaglutide in Routine Clinical Practice: 24-Month Real-World Effectiveness, Persistence and Safety in Adults With Type 2 Diabetes

Baldassarre MPA, Di Dalmazi G, Carrieri F, et al. (2026). Diabetes, Obesity and Metabolism. human humans, n=232, retrospective single-clinic cohort (Italy), adults with type 2 diabetes

Effects of Liraglutide and Semaglutide on Cardiometabolic Dysregulation and Oxidative Stress in an Experimental Model of Metabolic Syndrome

Ravić MP, Srejović IM, Andjić MM, et al. (2026). Medical Sciences. animal male Wistar rats with diet- and streptozotocin-induced metabolic syndrome (n not in abstract)